Trial Profile

Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary)
Indications Mycosis fungoides; Sezary syndrome; Skin disorders
Focus Therapeutic Use

Most Recent Events

09 Apr 2025 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.
09 Apr 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Jul 2026.
12 Dec 2023 The primary efficacy endpoint for cohort 1A was not met, leading to enrollment onto cohort 1B. To date, 14 of planned 19 pts enrolled onto cohort 1B.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com